Page last updated: 2024-12-07

mci 9038

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID92722
CHEMBL ID1166
CHEBI ID94385
SCHEMBL ID1145308
SCHEMBL ID20567702
MeSH IDM0100022

Synonyms (81)

Synonym
(2r,4r)-1-((s)-5-(diaminomethyleneamino)-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl)-4-methylpiperidine-2-carboxylic acid
(2r,4s)-1-[5-guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid
1-[5-guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid
(s)-1-[5-guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid
(2r,4r)-1-[(s)-5-guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid
bdbm50038001
1-[5-guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid (argatroban)
(2s,4s)-1-[5-guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid
1-[(2r,3s)-5-guanidino-2-(3-methyl-1,2,3,4-tetrahydro-quinoline-8-sulfonylamino)-pentanoyl]-4-methyl-piperidine-2-carboxylic acid
AB01275532-01
mci-9038
2-piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-
2-piperidinecarboxylic acid, 1-((2s)-5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2r,4r)-
(2r,4r)-4-methyl-1-((s)-n(sup 2)-(((rs)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid
argatrobanum [latin]
argatroban [inn:jan]
MLS001424093
argatroban
md-805
smr000466348
MLS000759461
argatroban anhydrous
DB00278
NCGC00166413-01
HMS2051N07
HMS2090L12
gn-1600
CHEMBL1166 ,
(2r,4r)-1-[(2s)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
(2r,4r)-4-methyl-1-[n-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-l-arginyl]-2-piperidinecarboxylic acid
(2r,4r)-1-((2s)-5-guanidino-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl)-4-methy
AKOS015919612
CCG-100933
(2r,4r)-1-[(2s)-5-guanidino-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methyl-piperidine-2-carboxylic acid
unii-ocy3u280y3
ocy3u280y3 ,
hsdb 8488
argatrobanum
NCGC00166413-03
S2069
(2r,4r)-1-((2s)-5-guanidino-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl)-4-methylpiperidine-2-carboxylic acid
(2r,4r)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(3r)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methyl-piperidine-2-carboxylic acid
gtpl6385
2-piperidinecarboxylic acid, 1-((2s)-5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, (2r,4r)- anhydrous
argatroban [who-dd]
argatroban [inn]
(2r,4r)-4-methyl-1-(n (sup 2)-((1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)-l-arginyl)pipecolic acid
argatroban [mi]
CCG-207885
AB00639932-04
HY-B0375
(2r,4r)-1-[(2s)-5-carbamimidamido-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl]-4-methylpiperidine-2-carboxylic acid
MLS006010033
smr004624627
NC00183
KXNPVXPOPUZYGB-IOVMHBDKSA-N
(2r,4r)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(3r)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methyl-pipe ridine-2-carboxylic acid
J-500992
J-500996
SCHEMBL1145308
AB01275532_02
sr-01000759392
SR-01000759392-4
sr-05000001529
SR-05000001529-2
CHEBI:94385
(2r,4r)-1-[(2s)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid
SR-05000001529-1
HMS3713D22
SCHEMBL20567702
-8-sulfonamido)pentanoyl)-4-methylpiperidine-2-carboxylic acid
(2r,4r)-1-((2s)-5-guanidino-2-(3-methyl-1,2,3,4-tetrahydroquinoline
BCP06831
AS-14191
Q27074501
BRD-A48261811-001-08-1
C72625
EX-A4276
74863-84-6 (anhydrous)
(2r,4r)-4-methyl-1-(((3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonyl)-l-arginyl)piperidine-2-carboxylic acid
EN300-19767223

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These results suggest that argatroban provides safe anticoagulation in acute ischemic stroke, warranting future studies powered to evaluate its efficacy and more precisely estimate event rates."( Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.
Brown, PM; Hursting, MJ; LaMonte, MP; Nash, ML; Schultz, J; Wang, DZ; Woolfenden, AR, 2004
)
0.32
"The combination of Argatroban and intravenous tPA is potentially safe in patients with moderate neurological deficits due to proximal intracranial arterial occlusions and may produce more complete recanalization than tPA alone."( The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
Alexandrov, AV; Balucani, C; Barlinn, K; Barreto, AD; Chen, Z; Demchuk, AM; Garami, Z; Gonzales, NR; Grotta, JC; Lee, J; Lyden, P; Martin-Schild, S; Mikulik, R; Pandurengan, R; Rahbar, MH; Savitz, SI; Shen, L; Sisson, A; Sugg, RM; Tsivgoulis, G; Wu, TC, 2012
)
0.38
"Argatroban is an effective and safe anticoagulation agent during elective PCI procedure, anticoagulant efficacy and risk of bleeding side effects of argatroban are similar to heparin."( [Anticoagulant efficacy and safety of argatroban for patients undergoing elective percutaneous coronary intervention].
Chen, YD; Gu, XF; Guo, J; Jin, QH; Liu, HB; Ma, YL; Sun, ZJ; Tian, F; Yan, F; Yu, H, 2013
)
0.39
" However, a safe dose which still provides effective thromboembolic prophylaxis without major bleeding still needs to be identified."( Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.
Baumgarten, G; Boehm, O; Graeff, I; Hoeft, A; Kim, SC; Schewe, JC; Tran, N; Wittmann, M, 2015
)
0.42
" Data on demographic and general clinical information, laboratory examination, adverse events, adverse reactions and serious adverse events in the two groups will be collected."( Evaluating the safety and efficacy of argatroban locking solution in the prevention of the dysfunction of haemodialysis central venous catheters: a study protocol for a randomized controlled trial.
Cai, G; Cao, X; Chen, X; Feng, Z; Li, J; Lin, S; Liu, C; Sun, X; Wang, Y; Wu, D; Wu, J; Zhang, L; Zhu, H, 2021
)
0.62
"This is the first report that short-term argatroban combined with DAPT seems to be safe and may effectively prevent END and improve neurological prognosis for acute mild to moderate ischemic stroke patients with LAA; however, interpretation of the conclusion required caution due to nonrandomized controlled trial with medium sample size."( Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis.
Chen, HS; Cui, Y; Hou, XW; Li, XQ; Tian, XF; Wang, XH; Zhou, ZH, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Mean values for argatroban area under the concentration-time curves (AUC0-inf), maximum concentration (Cmax), and half-life (t1/2) were similar between regimens."( Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
Benincosa, LJ; Di Cicco, RA; Hursting, MJ; Jorkasky, DK; Peng, L; Sheth, SB; Tran, JQ; Tucci, M, 1999
)
0.3
" Study 1: the pharmacokinetic profile was well described by a two-compartment model with first-order elimination; effect response and plasma argatroban concentrations were well correlated."( The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.
Hursting, MJ; Swan, SK, 2000
)
0.31
" The recovered amount was proportionate to the dosage and followed the expected kinetics with a half-life of <20 min."( Pharmacokinetics of argatroban in primates: evidence on endogenous uptake.
Ahmad, S; Ahsan, A; Fareed, J; Fu, K; Hoppensteadt, DA; Iqbal, O; Lewis, BE; Walenga, JM; Yang, LH, 2000
)
0.31
"The potential for pharmacokinetic interactions between argatroban and warfarin was studied."( Lack of pharmacokinetic interactions between argatroban and warfarin.
Brown, PM; Hursting, MJ, 2002
)
0.31
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" A 2-compartment model with first-order elimination adequately described the pharmacokinetic profile of argatroban over all 3 dosing groups."( Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto, K; Harder, S; Klinkhardt, U; Niethammer, M; Zeiher, A, 2011
)
0.37
"This article reviews the potential use of argatroban for the treatment of ACS and presents the pharmacokinetic data currently available."( Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Cruz-González, I; López-Jiménez, R; Perez-Rivera, A; Yan, BP, 2012
)
0.38
"Only limited data are available on the pharmacokinetic and pharmacodynamic properties of argatroban in critically ill patients under clinical conditions."( Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia.
Bek, MJ; Keyl, C; Trenk, D; Wiessner, M; Zimmer, E, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"The pharmacokinetic-pharmacodynamic (PK-PD) relationship of argatroban, administered in combination with a platelet glycoprotein IIb/IIIa receptor antagonist, was characterized in patients undergoing percutaneous coronary intervention (PCI)."( Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention.
Aluri, J; Boyle, DA; Cox, DS; Fossler, MJ; Holdbrook, F; Kleiman, NS; Parchman, LG, 2004
)
0.32
" Our experience indicates that medical therapy for hemolysis and suspected LVAD thrombosis with warfarin and eptifibatide alone or in combination with argatroban or heparin appears safe and may be effective, although the episodes of recurrent hemolysis after medical management remain high."( The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices.
Abramov, D; Birks, E; Bitar, A; Lenneman, A; Massey, T; Slaughter, M; Vijayakrishnan, R, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
"In an effort to prepare orally bioavailable analogs of our previously reported thrombin inhibitor 1, we have synthesized a series of compounds that utilize the unique amino acid D-dicyclohexylalanine as a P3 ligand."( Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
Appleby, SD; Baskin, EP; Chen, IW; Dancheck, KB; Gardell, SJ; Lewis, SD; Lucas, BJ; Lumma, WC; Lyle, EA; Lynch, JJ; Tucker, TJ; Vacca, JP; Woltmann, R, 1997
)
0.3
" However, NAPAP and other benzamidine derivatives do not show favorable pharmacological properties; above all, they have very low systemic bioavailability after oral administration."( Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
Hauptmann, J; Prasa, D; Stürzebecher, J; Vieweg, H; Wikström, P, 1997
)
0.3
"As part of an effort to prepare efficacious and orally bioavailable analogs of the previously reported thrombin inhibitors 1a, b, we have synthesized a series of compounds that utilize 3,3-disubstituted propionic acid derivatives as P3 ligands."( Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.
Appleby, SD; Baskin, EP; Chen, IW; Cooper, CM; Dancheck, KB; Gardell, SJ; Krueger, JA; Lewis, SD; Lucas, BJ; Lumma, WC; Lyle, EA; Lynch, JJ; Naylor-Olsen, AM; Sisko, JT; Tucker, TJ; Vacca, JP; Woltmann, RF, 1997
)
0.3
" Thirdly, oral bioavailability has been achieved while maintaining selectivity and efficacy through the incorporation of progressively less basic P1 groups."( Thrombin inhibitor design.
Naylor-Olsen, AM; Sanderson, PE, 1998
)
0.3
" By minimizing the size and lipophilicity of the P3 group and by incorporating hydrogen-bonding groups on the N-terminus or on the 2-position of the P1 aromatic ring, we have prepared a number of derivatives in this series that exhibit subnanomolar enzyme potency combined with good in vivo antithrombotic and bioavailability profiles."( Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
Baskin, EP; Brady, SF; Chen, IW; Cook, JJ; Cooper, CM; Dancheck, KB; Gardell, SJ; Holahan, MA; Krueger, JA; Lewis, SD; Lucas, BJ; Lumma, WC; Lyle, EA; Lynch, JJ; Naylor-Olsen, AM; Sisko, JT; Stauffer, KJ; Stranieri, MT; Tucker, TJ; Vacca, JP; Yan, Y, 1998
)
0.3
" For some of them oral bioavailability is claimed and they are effective in in vitro coagulation assays."( Advances in the development of thrombin inhibitors.
Hauptmann, J; Steinmetzer, T; Sturzebecher, J, 2001
)
0.31
" The bioavailability in rats and dogs could be drastically altered depending on the overall charge distribution in the molecule."( Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.
Adang, AE; de Man, AP; Grootenhuis, PD; Kelder, J; Lucas, H; Meuleman, DG; Peters, CA; Rewinkel, JB; Smit, MJ; van Aelst, S; van Boeckel, CA; van Dinther, T; Visser, A; Vogel, GM, 2002
)
0.31
" Fondaparinux has excellent bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without anticoagulant monitoring."( Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bauer, KA; Donati, MB; Gould, M; Hirsh, J; Samama, MM; Weitz, JI, 2008
)
0.35
" Considering the ideal route of administration in intensive care patients, peripheral vasoconstriction, edema, shock, and administration of catecholamines may reduce bioavailability and efficacy of subcutaneous administration of low molecular weight heparin (LMWH)."( [Anticoagulation in critically ill patient].
Fries, D, 2009
)
0.35
" Peripheral vasoconstriction, edema, shock, and administration of catecholamines may reduce the bioavailability and efficacy of subcutaneous administration of low molecular weight heparin."( Thrombosis prophylaxis in critically ill patients.
Fries, D, 2011
)
0.37
" Fondaparinux exhibits complete bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without coagulation monitoring."( Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Baglin, TP; Garcia, DA; Samama, MM; Weitz, JI, 2012
)
0.38
"The use of direct thrombin inhibitors (DTIs) for prophylactic or therapeutic anticoagulation is increasing because of the predictable bioavailability and short half-life of these DTIs."( Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers, J; Scharnhorst, V; Stroobants, AK; van de Kerkhof, D; van den Dool, EJ, 2012
)
0.38
" Its oral bioavailability in rats or dogs was not better than that of LB30870."( Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
Cho, KH; Kim, A; Kim, TH; Lee, SH; Park, HD, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The thrombin inhibitors were given intravenously, and complete concentration- and/or dose-response curves were constructed."( The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Deinum, J; Elg, M; Gustafsson, D, 1997
)
0.3
" Analysis of the argatroban dose-response data with a competitive inhibition model has yielded IC50 values in the low micromolar range."( No effect of clot age or thrombolysis on argatroban's inhibition of thrombin.
Hantgan, RR; Hursting, MJ; Jerome, WG, 1998
)
0.3
" Therefore, coadministration of CYP3A4/5 inhibitors should not require a modification in the dosage of argatroban."( Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
Benincosa, LJ; Di Cicco, RA; Hursting, MJ; Jorkasky, DK; Peng, L; Sheth, SB; Tran, JQ; Tucci, M, 1999
)
0.3
" The next highest dosing group (2."( Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model.
Itoh, T; Naitoh, K; Narita, Y; Natsuaki, M; Ohteki, H; Sakai, M, 1999
)
0.3
" A reduced dose of the thrombin inhibitor with the standard dose of the antiplatelet drug was the dosing regimen used."( Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Bakhos, M; Fareed, J; Jeske, WP; Lewis, BE; Leya, F; Walenga, JM; Wallis, DE, 1999
)
0.3
" Dosing precautions are recommended, however, in patients with hepatic dysfunction."( The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.
Hursting, MJ; Swan, SK, 2000
)
0.31
" The recovered amount was proportionate to the dosage and followed the expected kinetics with a half-life of <20 min."( Pharmacokinetics of argatroban in primates: evidence on endogenous uptake.
Ahmad, S; Ahsan, A; Fareed, J; Fu, K; Hoppensteadt, DA; Iqbal, O; Lewis, BE; Walenga, JM; Yang, LH, 2000
)
0.31
"To evaluate and compare the relationship between dosage and coagulation parameters, as well as safety profiles, of ascending bolus and infusion dosages of argatroban versus heparin in three phase I studies."( Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
Hursting, MJ; Lambrecht, LJ; St Peter, JV; Swan, SK, 2000
)
0.31
" Effect steady state was attained by five or more subjects per dosing group receiving argatroban (5-9) but typically two or fewer subjects per group receiving heparin (0-7)."( Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
Hursting, MJ; Lambrecht, LJ; St Peter, JV; Swan, SK, 2000
)
0.31
" An argatroban dosage of 100 microg/kg bolus plus 3 microg/kg/min infusion for 72 hours was selected for the randomized study in which 82 patients were allocated to argatroban and 45 to heparin (5000 U intravenous bolus, 1000 U/h infusion)."( Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.
Besse, P; Darius, H; Fels, PW; Fitzgerald, D; Garrigou, D; Müller, E; Puel, J; Simoons, ML; Vahanian, A; Van de Werf, F; Vermeer, F, 2000
)
0.31
" However, for use in prophylaxis of thrombotic diseases such inhibitors should be orally available, must be safe to avoid bleeding complications and should have an appropriate half-life, allowing once or twice daily dosing to maintain adequate antithrombotically effective blood levels."( Advances in the development of thrombin inhibitors.
Hauptmann, J; Steinmetzer, T; Sturzebecher, J, 2001
)
0.31
" To confirm the lack of antibodies in argatroban-treated patients with HIT, we examined plasma for anticoagulant-altering activity and reviewed dosing patterns of re-exposed patients."( Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.
Ahmad, S; Hoppensteadt, D; Hursting, MJ; Iqbal, O; Lewis, BE; Walenga, JM, 2002
)
0.31
" In practice, argatroban coadministered with these frequently prescribed drugs should require no dosage adjustments."( Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin.
DiCicco, RA; Graham, AM; Hursting, MJ; Inglis, AM; Sheth, SB; Tenero, DM, 2002
)
0.31
" However, optimal dosing regimens have not been established in all cases."( Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Jeske, WP; Walenga, JM, 2002
)
0.31
" The main attributes of this synthetic drug are its rapid onset of anti-thrombin action, the rapid reversibility of its anticoagulant effect, potent inhibition of clot-bound thrombin, the absence of antibody formation and no need for dosage adjustment in patients with renal impairment."( [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin, HK, 2002
)
0.31
" Argatroban dosage at 350 microg/kg intravenous slow bolus followed by 25 microg/kg/min infusion was adequate to perform PTCA and stenting procedures."( Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology.
Ahmad, S; Fareed, J; Iqbal, O; Lewis, BE; Rangel, Y; Walenga, JM, 2002
)
0.31
" In this report, we describe a woman with primary antiphospholipid antibody syndrome who developed extensive pulmonary embolism despite receiving a proven therapeutic dosage of low molecular weight heparin."( Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome.
Ahmed, S; Karim, A; Mattana, J; Patel, D; Siddiqui, R, 2002
)
0.31
" Alternate agents such as the direct thrombin inhibitors (hirudin and argatroban) are available, but careful dosing and monitoring of the anticoagulant effect are required."( Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.
Kovalik, EC; O'Shea, SI; Ortel, TL,
)
0.13
" The main attributes of this synthetic drug are its rapid onset of anti-thrombin action, rapid reversibility of its anticoagulant effect, potent inhibition of clot-bound thrombin, absence of antibody formation and no need for initial dosage adjustment in patients with renal impairment."( An overview of the direct thrombin inhibitor argatroban.
Walenga, JM, 2002
)
0.31
" The main attributes of argatroban are its rapid onset of action, fast reversibility of its anticoagulant effect, inhibition of clot-bound thrombin, easily monitored by the aPTT and ACT and no dosage adjustment in renal-impaired individuals."( Argatroban in HIT type II and acute coronary syndrome.
Lewis, BE; Walenga, JM, 2002
)
0.31
" Argatroban does not generate any neutralizing or non-neutralizing antibodies and, therefore, it does not require any dosage adjustment during the course of therapy as other thrombin inhibitors require."( Practical issues in the development of argatroban: a perspective.
Fareed, J; Hoppensteadt, D; Iqbal, O; Lewis, BE; Tobu, M, 2002
)
0.31
"To retrospectively evaluate clinical experiences with argatroban dosing, particularly incremental dosage adjustments, during a clinical trial of argatroban anticoagulation in heparin-induced thrombocytopenia (HIT)."( Argatroban dosing in patients with heparin-induced thrombocytopenia.
Hursting, MJ; Verme-Gibboney, CN,
)
0.13
"Records of 304 patients with HIT administered argatroban during a prospective study were reviewed to determine each dose, incremental dosage adjustment, and duration of therapy."( Argatroban dosing in patients with heparin-induced thrombocytopenia.
Hursting, MJ; Verme-Gibboney, CN,
)
0.13
"Based on this clinical experience, together with the established linear pharmacokinetics and pharmacodynamics of argatroban, appropriate dosage increments may be proposed for argatroban-treated patients with HIT."( Argatroban dosing in patients with heparin-induced thrombocytopenia.
Hursting, MJ; Verme-Gibboney, CN,
)
0.13
" Dosing in these patients requires very careful management."( Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
Dager, WE; White, RH, 2003
)
0.32
" The available data, as well as our report, suggest that dosing adjustment during hemodialysis may not be necessary in patients without associated hepatic dysfunction."( Decreased argatroban clearance unaffected by hemodialysis in anasarca.
de Denus, S; Spinler, SA, 2003
)
0.32
"To demonstrate dosing adjustment difficulties of argatroban encountered in critically ill patients with acute liver dysfunction who are receiving continuous renal replacement therapy."( Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.
Albert, M; Boulanger, I; Grégoire, G; Tardif, M; Williamson, DR, 2004
)
0.32
"Argatroban was started at the usual dosage of 2 microg/kg/minute, which resulted in significant overshooting of the aPTT and international normalized ratio (INR)."( Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.
Albert, M; Boulanger, I; Grégoire, G; Tardif, M; Williamson, DR, 2004
)
0.32
" However, in all patients with suspected liver dysfunction due to recent elevation of liver transaminase levels and combined renal failure, a decrease in the initial dosage and careful titration of the infusion are mandatory."( Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.
Albert, M; Boulanger, I; Grégoire, G; Tardif, M; Williamson, DR, 2004
)
0.32
"Coagulability related to CPB was controlled by the appropriate ARG dosage without the use of heparin in dogs."( Heparinless cardiopulmonary bypass with argatroban in dogs.
Itoh, T; Naito, K; Natsuaki, M; Ohtsubo, S; Okazaki, Y; Rikitake, K, 2004
)
0.32
"0 microg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3)."( Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Breddin, HK; Graff, J; Harder, S; Klinkhardt, U; Osakabe, M; von Hentig, N; Walenga, JM; Watanabe, H, 2004
)
0.32
" Optimal dosing regimens for argatroban, lepirudin, and bivalirudin should be further established in PCI patients."( Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia.
Dangas, GD; Nikolsky, E, 2004
)
0.32
" Previous reports regarding the use of argatroban and other nonheparin anticoagulants for anticoagulation are reviewed and suggestions regarding argatroban dosing in infants are presented."( Argatroban for anticoagulation during cardiopulmonary bypass in an infant.
Dyke, PC; Mureebe, L; Russo, J; Russo, P; Tobias, JD, 2005
)
0.33
" Despite the low number of patients argatroban seems to lead to a more stable anticoagulant response than lepirudin resulting in a lower variability of the dosage for prophylaxis or treatment of thromboembolism of patients with a history of HIT and lepirudin antibodies."( Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.
Fenyvesi, T; Harenberg, J; Ingrid, J; Job, H; Jörg, I; Lukas, P; Piazolo, L; Tivadar, F, 2005
)
0.33
" Peritransitional INRs, aPTTs, anticoagulant dosing patterns, and outcomes were evaluated in 165 HIT patients who were transitioned, without guidelines, from argatroban to warfarin therapy."( Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
Hursting, MJ; Lewis, BE; Macfarlane, DE, 2005
)
0.33
" Outcomes, safety, and dosing information were summarized."( Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Grossman, EJ; Hursting, MJ; Murray, PT; Reddy, BV; Trevino, SA, 2005
)
0.33
" Current dosing recommendations are adequate for these patients."( Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Grossman, EJ; Hursting, MJ; Murray, PT; Reddy, BV; Trevino, SA, 2005
)
0.33
" Low-molecular-weight heparins, available in the last 20 years, are manufactured from unfractionated heparin and have superior dose-response relationships because of fewer nonspecific reactions with plasma proteins and cells."( Heparin and other rapidly acting anticoagulants.
Hyers, TM, 2005
)
0.33
" Argatroban and lepirudin dosing and pharmacokinetics have not yet been established for young children."( Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
Hallisey, RK; John, TE, 2005
)
0.33
"Patients were assessed for dosage and duration of argatroban or lepirudin therapy, HIT diagnostic tests, and clinically significant adverse events."( Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Fish, DN; Jung, R; Kiser, TH; MacLaren, R, 2005
)
0.33
" The authors conducted a literature analysis to characterize the uses, dosing patterns, and safety of argatroban anticoagulation in pediatric patients."( Argatroban anticoagulation in pediatric patients: a literature analysis.
Dubb, J; Hursting, MJ; Verme-Gibboney, CN, 2006
)
0.33
"We evaluated the dosing requirements in argatroban-treated patients with heparin-induced thrombocytopenia (HIT) and hepatic dysfunction, and compared efficacy and safety outcomes with historical control patients."( Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
Hursting, MJ; Levine, RL; McCollum, D, 2006
)
0.33
" Argatroban, with proper initial dosing and monitoring, can provide safe and effective antithrombotic therapy in patients with HIT and hepatic impairment."( Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
Hursting, MJ; Levine, RL; McCollum, D, 2006
)
0.33
" Diagnostic and therapeutic challenges include frequency of thrombocytopenia after cardiopulmonary bypass, imperfect laboratory testing, lack of established dosing of alternative anticoagulants (such as argatroban and lepirudin), and increased anticoagulant-related bleeding in young children."( Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients.
Boshkov, LK; Kirby, A; Shen, I; Ungerleider, RM, 2006
)
0.33
" We retrospectively evaluated the effect of renal function on argatroban therapy in HIT patients with normal hepatic function, with the goal of refining dosing guidance, if needed."( Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
Guzzi, LM; Hursting, MJ; McCollum, DA, 2006
)
0.33
"We retrospectively evaluated the effect of renal function on argatroban therapy in HIT patients with normal hepatic function, with the goal of refining current dosing guidance, if needed."( Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
Guzzi, LM; Hursting, MJ; McCollum, DA, 2006
)
0.33
" In this article, the recognition and treatment of HIT is discussed, and a practical dosing protocol for argatroban therapy that has been developed and used successfully by the nurses and physicians at Holy Cross Hospital in Ft."( Treatment of heparin-induced thrombocytopenia: a practical argatroban dosing protocol for nurses.
Cypher, S,
)
0.13
" This analysis focused on patient characteristics, type of surgery, argatroban dosing schedule, monitoring of anticoagulation and outcomes."( Argatroban for anticoagulation during cardiac surgery.
Kloecker, GH; Laber, DA; Martin, ME, 2007
)
0.34
" Recent data indicate that the approved dosing regimens of the direct thrombin inhibitors are too high, especially in ICU patients."( Heparin-induced thrombocytopenia in intensive care patients.
Greinacher, A; Selleng, K; Warkentin, TE, 2007
)
0.34
"Despite long-term use of argatroban in clinical practice, no dosing recommendations exist for critically ill patients with multiple organ dysfunction (MODS) and suspected or proven heparin-induced thrombocytopenia (HIT)."( Argatroban anticoagulation in critically ill patients.
Beiderlinden, M; Görlinger, K; Peters, J; Treschan, TA, 2007
)
0.34
" Argatroban dosage patterns, aPTTs and platelet count responses, and 37-day outcomes (death, amputation, new thrombosis, major bleeding) were summarised for patients stratified by age (65-74 years [n = 31]; 75-84 years [n = 26]; >/=85 years [n = 5]) to identify possible age-related trends."( Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
Bartholomew, JR; Hursting, MJ; Pietrangeli, CE, 2007
)
0.34
"Argatroban can be used effectively and safely to manage HIT in females, with dosing requirements, aPTT responses, and clinical outcomes comparable to those in men."( Argatroban therapy in women with heparin-induced thrombocytopenia.
Anglade, E; Baron, SJ; Hursting, MJ; Jang, IK,
)
0.13
" It is widely believed that no dosage adjustment is required in patients with renal insufficiency, making it a preferred agent in patients on renal replacement therapy (Reddy and Grossman, Ann Pharm 2005;39:1601-1605)."( Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia.
Athar, U; Gajra, A; Hudson, J; Husain, J; Lynch, J, 2008
)
0.35
" DTIs have antiplatelet effects, anticoagulant action, and most do not bind to plasma proteins, thereby providing a more consistent dose-response effect than UFH."( Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Lepor, NE, 2007
)
0.34
"In a retrospective review of 10 patients with known or suspected HIT over a two-year period, medical records were evaluated for baseline laboratory results, treatment selection, initial dosing and monitoring, discontinuation of heparin, and alternative therapies chosen."( Standardizing the management of heparin-induced thrombocytopenia.
Chiappe, J; Fugate, S, 2008
)
0.35
"To characterize dosing requirements, aPTTs, factors affecting dosage, and clinical outcomes in patients administered argatroban after coronary artery bypass graft (CABG) surgery."( Reduced argatroban doses after coronary artery bypass graft surgery.
Czyz, Y; Hoffman, WD; Hursting, MJ; McCollum, DA, 2008
)
0.35
" Patient characteristics, argatroban dosing information, aPTTs (target range 45-90 sec), and outcomes were summarized."( Reduced argatroban doses after coronary artery bypass graft surgery.
Czyz, Y; Hoffman, WD; Hursting, MJ; McCollum, DA, 2008
)
0.35
"Patient features, argatroban dosing patterns, and aPTTs were similar among groups."( Reduced argatroban doses after coronary artery bypass graft surgery.
Czyz, Y; Hoffman, WD; Hursting, MJ; McCollum, DA, 2008
)
0.35
" Prospective study of reduced initial dosing in this setting is warranted."( Reduced argatroban doses after coronary artery bypass graft surgery.
Czyz, Y; Hoffman, WD; Hursting, MJ; McCollum, DA, 2008
)
0.35
"Acute physiologic changes after bypass graft surgery may temporarily result in reduced drug elimination and dosing requirements for the desired effect."( Considerations for drug dosing post coronary artery bypass graft surgery.
Dager, WE, 2008
)
0.35
" Important drug-specific limitations and dosing and monitoring guidelines must be respected for patient safety."( The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.
Prechel, M; Walenga, JM, 2008
)
0.35
" This literature analysis aimed to determine the effects of renal function on argatroban pharmacokinetics, pharmacodynamics, and its therapeutic dose in HIT and to evaluate argatroban dosing and safety during renal replacement therapy (RRT) and in adults with renal dysfunction undergoing surgical or invasive procedures."( Argatroban anticoagulation in renal dysfunction: a literature analysis.
Hursting, MJ; Murray, PT, 2008
)
0.35
"We retrospectively evaluated argatroban dosing patterns, clinical outcomes, and the effects of heart failure and multiple organ system failure on dosing requirements in 65 adult, intensive care patients administered argatroban anticoagulation for clinically suspected heparin-induced thrombocytopenia (n=56) or history of heparin-induced thrombocytopenia (n=9)."( Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.
Baghdasarian, SB; Bartholomew, JR; Begelman, SM; Hursting, MJ; Militello, MA; Singh, IM,
)
0.13
" The drug requires no dosage adjustments for age, sex, or renal impairment, including in dialysis-dependent patients."( Treatment of intracardiac thrombi with argatroban.
Janssens, U; Kroner, S; Lejczyk, J; Niedeggen, A; Reith, S; Stortz, C, 2008
)
0.35
"We retrospectively evaluated dosing patterns and 37-day outcomes in argatroban-treated African American (n = 52), Asian (n = 13), and Hispanic (n = 14) patients with heparin-induced thrombocytopenia (HIT)."( Dosing patterns and outcomes in African American, Asian, and Hispanic patients with heparin-induced thrombocytopenia treated with argatroban.
Hursting, MJ; Jang, IK, 2009
)
0.35
" An argatroban infusion was started at 2 microg/kg/minute during her 33rd week of pregnancy, with the dosage titrated based on the activated partial thromboplastin time; infusion rates ranged from 2-8 microg/kg/minute."( Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature.
Al-Mondhiry, HA; Ambrose, A; Botti, JJ; Vaida, SJ; Young, SK, 2008
)
0.35
" These predictors identify decreased argatroban dosing requirements resulting in effective and safe CRRT."( Argatroban for anticoagulation in continuous renal replacement therapy.
Böhm, M; Girndt, M; Link, A; Mathes, A; Rensing, H; Selejan, S, 2009
)
0.35
" The magnitude of dosage alteration in relation to severity of organ failure is unknown."( Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
Ernst, NE; Gallagher, EM; Keegan, SP; Mueller, EW; Young, EJ, 2009
)
0.35
" Critically ill patients required lower mean +/- SD therapeutic argatroban dosage (0."( Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
Ernst, NE; Gallagher, EM; Keegan, SP; Mueller, EW; Young, EJ, 2009
)
0.35
" Because of an inverse relationship with SOFA score, initial argatroban dosage in critically ill patients should be based on the presence and magnitude of organ failure."( Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
Ernst, NE; Gallagher, EM; Keegan, SP; Mueller, EW; Young, EJ, 2009
)
0.35
"Patients with suspected or documented HIT at an 800-bed teaching community hospital were prospectively treated, in a nonrandomized, nonblinded manner, with argatroban; dosage adjustments were made according to 1 of 2 variations of a dosing nomogram: standard or hepatic/critically ill."( Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
Ansara, AJ; Arif, S; Warhurst, RD, 2009
)
0.35
"The nomogram is an effective dosing tool for achieving and maintaining therapeutic levels of anticoagulation."( Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
Ansara, AJ; Arif, S; Warhurst, RD, 2009
)
0.35
" About anticoagulation during cardiopulmonary bypass (CPB), activated clotting time (ACT) was maintained than 400 seconds, using the continuance dosage together with the bolus dosage of argatroban."( [Use of argatroban during cardiopulmonary bypass for atrial septal defect with heparin induced thrombocytopenia after introduction of dialysis].
Ishida, H; Yamazaki, T, 2009
)
0.35
" Recommendations for dosing of argatroban in HIT patients with and without comorbities are presented."( [Argatroban treatment of heparin-induced immune-mediated thrombocytopenia].
Heslet, L; Nielsen, JD, 2009
)
0.35
"Both ICU and non-ICU patients require less than the manufacturer-recommended initial dosage of argatroban."( Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
Balasubramaniam, M; Forsyth, LL; Koerber, JM; Mattson, JC; Priziola, JL; Smythe, MA, 2009
)
0.35
" Despite high dosing and long-term application of argatroban, anticoagulation remained uncritical and was well controllable by monitoring the activated partial thromboplastin time."( [Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient: therapy management using the direct thrombin inhibitor argatroban].
Heil, S, 2009
)
0.35
" Dosing of the direct thrombin inhibitor argatroban depends on the severity of illness (SAPS II-score) and is up to 10-times lower than in patients without critical illness."( [Anticoagulation in critically ill patient].
Fries, D, 2009
)
0.35
" The literature on the subject is reviewed and the relationship between argatroban dosage and activated clotting time (ACT) is studied by regression analysis."( Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?
D'Ancona, G; Filippone, G; Floriano, M; Follis, F; Follis, M; Lobianco, E; Montalbano, G, 2010
)
0.36
"05) relationship was disclosed between increasing dosage and ACT, while the same relationship was absent on decreasing dosage."( Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?
D'Ancona, G; Filippone, G; Floriano, M; Follis, F; Follis, M; Lobianco, E; Montalbano, G, 2010
)
0.36
" At concentrations higher than the "therapeutic" levels, the dose-response curve in the Ks assay became very steep for lepirudin while those were shallow for the others."( The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
Bark, N; Blombäck, M; He, S; Johnsson, H; Wallén, NH, 2010
)
0.36
"The objective was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of argatroban in pediatric patients and derive dosing recommendations."( Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics.
Boyle, DA; Choi, YM; Cox, DS; Gobburu, JV; Hossain, M; Madabushi, R; Patel, BR; Young, G, 2011
)
0.37
" Limited and inconsistent data exist about dosing of argatroban in intensive care unit (ICU) patients with critical illnesses."( Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
Huber, W; Moessmer, G; Phillip, V; Saugel, B; Schmid, RM, 2010
)
0.36
" A decrease in the initial dosage is mandatory in this patient population."( Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
Huber, W; Moessmer, G; Phillip, V; Saugel, B; Schmid, RM, 2010
)
0.36
" A 2-compartment model with first-order elimination adequately described the pharmacokinetic profile of argatroban over all 3 dosing groups."( Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto, K; Harder, S; Klinkhardt, U; Niethammer, M; Zeiher, A, 2011
)
0.37
" The studies were similar in design with respect to patient inclusion and exclusion criteria, the argatroban dosing regimen, and primary efficacy outcomes."( Argatroban in the management of heparin-induced thrombocytopenia.
Babuin, L; Pengo, V, 2010
)
0.36
"Despite the growing epidemic of obesity in the United States, dosing medications in such patients remains poorly studied and understood."( Pharmacotherapy in the critically ill obese patient.
Medico, CJ; Walsh, P, 2010
)
0.36
" Data regarding demographics, direct thrombin inhibitor (DTI) dosing and monitoring, and related clinical outcomes were collected; statistical analysis was performed to compare results for patients receiving bivalirudin versus those receiving argatroban."( Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
Arnold, H; Deal, EN; Hollands, JM; Martinez, EJ; Micek, ST; Skrupky, LP; Smith, JR, 2010
)
0.36
" Activated partial thromboplastin time (APTT) value was monitored in the argatroban group at different sites and time points to adjust the dosage during IVVH."( Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
Chen, X; Chen, Y; Ma, Z; Sun, X; Wang, Y; Xiang, J; Xiao, Q; Zhou, J, 2011
)
0.37
" Protocol patients had DTI initial doses based on organ function and fixed dosage adjustments of 10, 25, or 50%."( Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.
Hassell, KL; Kiser, TH; Mann, AM; Trujillo, TC, 2011
)
0.37
" Severity of illness and SAPS II-score determine dosing of the direct thrombin inhibitor argatroban which needs to be about 10-times lower than in patients without critical illness."( Thrombosis prophylaxis in critically ill patients.
Fries, D, 2011
)
0.37
" As such, studies evaluating the safety, efficacy, and dosing of alternative anticoagulants are required."( Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.
Boshkov, LK; Boyle, DA; Cox, DS; Hursting, MJ; Kallender, H; Raffini, LJ; Soffer, J; Sullivan, JE; Tarka, EA; Young, G, 2011
)
0.37
" An ongoing issue is the appropriate dosing of argatroban in special patient groups."( Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective.
Alatri, A; Armstrong, AE; Greinacher, A; Koster, A; Kozek-Langenecker, SA; Lancé, MD; Link, A; Nielsen, JD; Sandset, PM; Spanjersberg, AJ; Spannagl, M, 2012
)
0.38
" The implementation of the HIT protocol has resulted in greater compliance with appropriate DTI dosing and improved EMR documentation of HIT."( Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol.
Corbets, LR; Forsyth, LL; Koerber, JM; Mehta, TP; Melendy, SM; Parikh, R; Smythe, MA; Sykes, E, 2012
)
0.38
" There have been few experiences published involving the pediatric population and controversy exists regarding the properties and optimal dosing of these drugs."( Alternative anticoagulation during cardiovascular procedures in pediatric patients with heparin-induced thrombocytopenia.
Argueta-Morales, IR; DeCampli, WM; Felix, DE; Munro, HM; Olsen, MC, 2012
)
0.38
" Nevertheless, this recommended dose is largely based on data from patients with more moderate liver disease (eg, Child-Pugh class A or B), and dosing in more advanced liver disease remains largely unexplored."( Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by child-pugh class C liver disease.
Rondina, MT; Varedi, A; Walker, A; Yarbrough, PM, 2012
)
0.38
"This report illustrates the importance of careful selection of argatroban dosing and appropriate aPTT monitoring in patients with severe liver disease."( Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by child-pugh class C liver disease.
Rondina, MT; Varedi, A; Walker, A; Yarbrough, PM, 2012
)
0.38
"A retrospective chart review was conducted to compare selected outcome measures between cohorts of adults who received argatroban or bivalirudin therapy for suspected heparin-induced thrombocytopenia (HIT) before (n = 25) and after (n = 25) the implementation of an institutional DTI protocol under which properly trained and credentialed pharmacists have a primary role in dosing and monitoring DTI infusions."( Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors.
Cooper, T; Kokko, H; Mazur, J; Taber, D; Uber, WE; White, CL, 2012
)
0.38
"Adequate monitoring of the effect of the direct thrombin inhibitor argatroban may facilitate individualized dosing and perioperative management of anticoagulation."( Ecarin modified rotational thrombelastometry: a point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban.
Hacker, S; Kozek-Langenecker, S; Schaden, E; Schober, A, 2013
)
0.39
" The second study looked at monitoring dabigatran with plasma-diluted thrombin time and found a linear relationship between the plasma-diluted thrombin time and the dabigatran dose-response curve."( Alternative monitoring of argatroban using plasma-diluted thrombin time.
Chandler, W; Hart, SR; Liebl, MG; Putney, D; Wanat, MA, 2013
)
0.39
" Dosage was reduced because of preoperative congestive liver disorder."( Non-recovery of ACT in a patient with heparin-induced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation.
Matsumoto, K; Nakagawachi, A; Sakaguchi, Y; Tanigawa, Y; Torikai, A; Yamada, T, 2013
)
0.39
" We were unable to achieve an increase in aPTT, despite aggressive argatroban dosing in a patient with increased factor VIII activity."( Apparent argatroban resistance in a patient with elevated factor VIII levels.
Alaniz, C; Kennedy, DM,
)
0.13
"With the initiation of argatroban therapy, particular attention should be given to ensure that aPTTs correlate with dosing to prevent life-threatening bleeding complications."( Apparent argatroban resistance in a patient with elevated factor VIII levels.
Alaniz, C; Kennedy, DM,
)
0.13
"No study has compared 2 different dosing strategies for argatroban titration nor has any published nomogram demonstrated improvement in outcomes."( Evaluation of 2 nomogram-based strategies for dosing argatroban in patients with known or suspected heparin-induced thrombocytopenia.
Arpino, PA; Fatalo, A; Goeller, AJ; Van Cott, EM, 2015
)
0.42
" The authors recommend caution while dosing dabigatran in the Asian population, as the estimates of kidney functioning vary substantially depending on the formula used to estimate GFR, which may in turn lead in some cases of inadequate dosing of dabigatran."( A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Azuma, S; Lum, CJ, 2013
)
0.39
" DTI use is also complicated by the imprecision of available monitoring tests and currently recommended dosing has been shown to result in a supratherapeutic anticoagulative state."( The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution.
Ashton, RF; Cairns, BA; Charles, AG; Khoury, AI; Phillips, MR, 2014
)
0.4
" Patient records were perused for preexisting history of HIT, heparin dosage before HIT, argatroban dosage, number of transfusions required, thromboembolic complications and length of ICU stay (ICU LOS)."( Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.
Baumgarten, G; Boehm, O; Graeff, I; Hoeft, A; Kim, SC; Schewe, JC; Tran, N; Wittmann, M, 2015
)
0.42
"To evaluate the safety, effectiveness, and dosing of off-label bivalirudin to argatroban and lepirudin in patients with heparin-induced thrombocytopenia (HIT) using a new pharmacist driven protocol."( Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
Bain, J; Meyer, A, 2015
)
0.42
"A central challenge in designing and administering effective anticoagulants is achieving the proper therapeutic window and dosage for each patient."( A novel, rapid method to compare the therapeutic windows of oral anticoagulants using the Hill coefficient.
Chang, JB; Karan, C; Quinnies, KM; Rand, JH; Realubit, R; Tatonetti, NP, 2016
)
0.43
" Knowledge of baseline values prior to DTI therapy and inclusion of clinical settings are essential for dosing DTIs when using aPTT."( Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Kolde, HJ; Seidel, H, 2018
)
0.48
" In addition, other modalities, such as continuous renal replacement therapy, may further complicate dosing strategies."( Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration.
Lopez, ND; Sin, JH, 2017
)
0.46
" Further studies are needed to confirm these results and determine the optimal dosing regimen."( Anticoagulation of Percutaneous Ventricular Assist Device Using Argatroban-Based Purge Solution: A Case Series.
Blum, EC; Martz, CR; Nemeh, H; Selektor, Y; Smith, ZR; To, L, 2018
)
0.48
" ACT was measured every 2 to 4 hours and remeasured 1 hour after each dosage adjustment."( Heparin-Induced Thrombocytopenia in Infants after Heart Surgery.
Abdillah, JN; Chen, X; Hu, Q; Huang, L; Luo, W; Zhou, W, 2019
)
0.51
" The great fluctuation in argatroban dosage during the course of HIT treatment necessitates close monitoring."( Heparin-Induced Thrombocytopenia in Infants after Heart Surgery.
Abdillah, JN; Chen, X; Hu, Q; Huang, L; Luo, W; Zhou, W, 2019
)
0.51
" This was a retrospective, single-center, cohort study that aimed to compare argatroban dosing requirements in those receiving extracorporeal life support (ECLS), continuous renal replacement therapy (CRRT), or neither."( Argatroban dosing requirements in extracorporeal life support and other critically ill populations.
Coba, VE; Dingman, JS; Peters, MA; Smith, ZR; To, L, 2020
)
0.56
" The rational for divergent dosing and monitoring approaches are discussed in this paper."( Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review.
Capoccia, M; Geli, J; Maybauer, DM; Maybauer, MO, 2022
)
0.72
" In these situations, the type, dosage or the time of last intake of anticoagulants is often unknown and single substance analysis by functional tests is only possible if the substance contained in the sample is known."( Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.
Beyer-Westendorf, J; Brückner, L; Pietsch, J; Tiebel, O, 2022
)
0.72
" The objective of this work is to define and verify the performance of a dosing protocol for the anti-IIa activity of the argatroban from the STA ECA-II reagent (Diagnostica Stago) and compare them to the Hemoclot Thrombin Inhibitor proposed by Hyphen Biomed based on diluted thrombin time."( [Performance evaluation of the STA ECA-II reagent for specific assay of anti-IIa activity of argatroban].
Genin, A, 2021
)
0.62
" Yet, caution is advised with regard to dosing of argatroban especially in sepsis."( Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review.
Asmis, LM; Bachler, M; Fries, D; Koscielny, J; Lang, T; Nowak, H; Paulus, P; Schewe, JC; von Heymann, C, 2022
)
0.72
" This study compared dose-response curves for dTT and aPTT in pediatric patients receiving argatroban and bivalirudin."( Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients.
Chandler, WL; Friedland-Little, JM; Hasan, RA; Kirk, CJ; Pak, J, 2023
)
0.91
" The dTT was fivefold more likely to show a stable dose-response slope than the aPTT (P < ."( Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients.
Chandler, WL; Friedland-Little, JM; Hasan, RA; Kirk, CJ; Pak, J, 2023
)
0.91
" Secondary endpoints included the type of thrombotic events, prevalence of ECMO-related major bleeding events, bleeding sites, ICU mortality, mortality during ECMO, liver and kidney function, thrombelastogram, blood transfusion, dosage of argatroban, the dynamic changes of coagulation variables 4 days before and 7 days after argatroban treatment."( [Application of argatroban in patients receiving extracorporeal membrane oxygenation support: a case-control study].
Li, X; Li, Y; Sun, B; Tang, X; Tong, Z; Wang, R; Zhang, Z, 2022
)
0.72
"Although intravenous (IV) direct thrombin inhibitors (DTI) have gained interest in pediatric extracorporeal membrane oxygenation (ECMO), dosing and safety information is limited."( Anticoagulation with Intravenous Direct Thrombin Inhibitors in Pediatric Extracorporeal Membrane Oxygenation: A Systematic Review of the Literature.
Betensky, M; Do, NL; Goldenberg, NA; Kiskaddon, AL; Williams, P, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency12.28610.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)IC50 (µMol)0.22000.00000.710710.0000AID1202328; AID1254403; AID1332061; AID1871815; AID210661; AID210667; AID210678; AID211550; AID257295; AID311535; AID766517; AID766518
ProthrombinHomo sapiens (human)Ki0.01840.00000.78469.0000AID1454782; AID211004; AID211014; AID211044; AID211187; AID211230; AID211597; AID238527; AID766529
Prothrombin Bos taurus (cattle)Ki0.04390.00112.06948.3700AID1454783; AID213277; AID213279
Coagulation factor XHomo sapiens (human)IC50 (µMol)134.00000.00030.593710.0000AID51829
Coagulation factor XHomo sapiens (human)Ki53.00000.00000.47089.0000AID766528
PlasminogenHomo sapiens (human)Ki257.00000.01701.15604.4000AID766525
Tissue-type plasminogen activatorHomo sapiens (human)Ki87.80000.01703.71968.6000AID766526
Cationic trypsinBos taurus (cattle)Ki2.90000.00001.07539.0000AID215212
Trypsin-1Homo sapiens (human)Ki1.99000.00001.76768.9000AID766527
Trypsin-2Homo sapiens (human)Ki1.99000.00430.94873.2900AID766527
Trypsin-3Homo sapiens (human)Ki1.99000.00430.94873.2900AID766527
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)Kd0.00240.00000.01010.0387AID766520
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (64)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisProthrombin Bos taurus (cattle)
acute-phase responseProthrombin Bos taurus (cattle)
positive regulation of blood coagulationProthrombin Bos taurus (cattle)
protein polymerizationProthrombin Bos taurus (cattle)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
response to hypoxiaTissue-type plasminogen activatorHomo sapiens (human)
proteolysisTissue-type plasminogen activatorHomo sapiens (human)
blood coagulationTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
protein modification processTissue-type plasminogen activatorHomo sapiens (human)
fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of proteolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
prevention of polyspermyTissue-type plasminogen activatorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionTissue-type plasminogen activatorHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTissue-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationTissue-type plasminogen activatorHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
proteolysisTrypsin-3Homo sapiens (human)
digestionTrypsin-3Homo sapiens (human)
antimicrobial humoral responseTrypsin-3Homo sapiens (human)
zymogen activationTrypsin-3Homo sapiens (human)
endothelial cell migrationTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombin Bos taurus (cattle)
calcium ion bindingProthrombin Bos taurus (cattle)
protein bindingProthrombin Bos taurus (cattle)
fibrinogen bindingProthrombin Bos taurus (cattle)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
serine-type endopeptidase activityTissue-type plasminogen activatorHomo sapiens (human)
signaling receptor bindingTissue-type plasminogen activatorHomo sapiens (human)
protein bindingTissue-type plasminogen activatorHomo sapiens (human)
phosphoprotein bindingTissue-type plasminogen activatorHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-3Homo sapiens (human)
calcium ion bindingTrypsin-3Homo sapiens (human)
protein bindingTrypsin-3Homo sapiens (human)
serine-type peptidase activityTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
collagen-containing extracellular matrixTissue-type plasminogen activatorHomo sapiens (human)
extracellular regionTissue-type plasminogen activatorHomo sapiens (human)
cytoplasmTissue-type plasminogen activatorHomo sapiens (human)
cell surfaceTissue-type plasminogen activatorHomo sapiens (human)
secretory granuleTissue-type plasminogen activatorHomo sapiens (human)
apical part of cellTissue-type plasminogen activatorHomo sapiens (human)
extracellular exosomeTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexTissue-type plasminogen activatorHomo sapiens (human)
Schaffer collateral - CA1 synapseTissue-type plasminogen activatorHomo sapiens (human)
glutamatergic synapseTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular regionTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
tertiary granule lumenTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (169)

Assay IDTitleYearJournalArticle
AID766529Inhibition of human thrombin2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID233225Inhibition of trypsin, selectivity with respect to thrombin1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID242973Ki ratio of human alpha thrombin to activated protein C2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID766520Binding affinity to thrombin (unknown origin) by surface plasmon resonance analysis2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID51829Inhibitory activity against Coagulation factor X1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety.
AID26945Oral bioavailability2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.
AID1454782Inhibition of human plasma thrombin using chromogenix AB as substrate after 30 secs by UV-spectrophotometry2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID766515Ratio of IC50 for plasma clot-bound thrombin (unknown origin) to IC50 for free thrombin (unknown origin)2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID211004In vitro binding affinity by measuring the inhibition of human thrombin1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Design and synthesis of potent and highly selective thrombin inhibitors.
AID18651The fraction of free compound available in plasma of rat;not determined1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
AID215212Inhibition of bovine trypsin1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID211550Inhibitory activity against thrombin1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety.
AID1167013Profibrinolytic activity in tissue factor-induced human plasma exposed to exogenous tissue plasminogen activator assessed as time needed to lyse 50% fibrin clot by turbidimetric assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
How a β-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID766524Selectivity ratio of Ki for human factor 10a to Ki for human thrombin2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID52178Selectivity ratio of IC50 of Coagulation factor Xa relative to IC50 of human alpha thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
AID242968Ki ratio of human alpha thrombin to activated factor X2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID766518Inhibition of free thrombin (unknown origin) using S2238 as substrate2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID20845Number of occlusions was reported1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
AID1202328Inhibition of human thrombin using Ac-FVR-AMC as substrate incubated for 10 mins prior to substrate addition measured for 10 min by fluorescence assay2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.
AID210678Inhibitory activity against thrombin induced platelet aggregation1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID766528Inhibition of human factor 10a2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID233224Compound was tested for inhibition of tissue-type plasminogen activator (tissue plasminogen activator), selectivity with respect to thrombin1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID766519Inhibition of plasma clot-bound thrombin (unknown origin) using S2238 as substrate2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID238200Inhibitory activity against thrombin2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Conformation mining: an algorithm for finding biologically relevant conformations.
AID1423543Anticoagulant activity in Swiss albino mouse assessed as tail bleeding time at 50 mg/kg, iv measured after 5 hrs (Rvb = 45.3 +/- 2.5 sec)2018Journal of natural products, 11-26, Volume: 81, Issue:11
First Report of Plant-Derived β-Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model.
AID130477ID50 is the dose required for 50% mice survival2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
AID1871815Inhibition of thrombin in human blood using fluorogenic Ac-FVR-AMC as substrate incubated for 10 mins by fluorescence based microplate reader method2022European journal of medicinal chemistry, Jan-15, Volume: 228Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
AID169106The 2(APTT) value is defined as the concentration of compound in plasma required to double the activated partial thromboplastin time in rat; Not determined1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID234945Selectivity is the ratio of Ki's against inhibition of thrombin and trypsin1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Design and synthesis of potent and highly selective thrombin inhibitors.
AID1423542Anticoagulant activity in Swiss albino mouse assessed as increase in activated partial thromboplastin time at 50 mg/kg, iv measured after 5 hrs relative to control2018Journal of natural products, 11-26, Volume: 81, Issue:11
First Report of Plant-Derived β-Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model.
AID466995Antithrombotic activity in Sprague-Dawley rat deep vein thrombosis model assessed as decrease in thrombus weight at 1 mg/kg, iv administered for 45 mins measured after 30 mins post dose relative to control2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
AID196087Ex vivo concentration of inhibitor to double the activated clotting time was measured in rat plasma2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
AID196210Concentration required to double the activated partial thromboplastin time (2X APTT) in FeCl3 induced thrombosis in rat carotid artery infused at 10 micro g/kg/min by intravenous administration; Not determined1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
AID19823Partition coefficient (logP)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
AID210667In vitro inhibitory activity against hydrolysis of human alpha thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
AID89375Concentration for doubling of thrombin time1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
AID210582Selectivity ratio of IC50 of Tissue plasminogen activator relative to IC50 of human alpha thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
AID89173The 2(APTT) value is defined as the concentration of compound in plasma required to double the activated partial thromboplastin time in human1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
AID211044In vitro inhibition constant (Ki) against human thrombin2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
AID90300Concentration required to double the activated partial thromboplastin time (2X APTT) in FeCl3 induced thrombosis in human carotid artery infused at 10 ug/kg/min by intravenous administration.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
AID766521Selectivity ratio of Ki for human t-PA to Ki for human thrombin2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID158010Selectivity ratio of IC50 of human plasmin relative to IC50 of human alpha thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
AID196090In vitro concentration of inhibitor to double the activated partial thromboplastin time was evaluated in rat2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
AID1332061Inhibition of human thrombin assessed as reduction in release of free nitroaniline using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometer2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.
AID233222Compound was tested for inhibition of plasmin, selectivity with respect to thrombin1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID233221Compound was tested for inhibition of activated protein C. selectivity with respect to thrombin1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID766522Selectivity ratio of Ki for human trypsin to Ki for human thrombin2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1423541Anticoagulant activity in Swiss albino mouse assessed as increase in prothrombin time at 50 mg/kg, iv measured after 5 hrs relative to control2018Journal of natural products, 11-26, Volume: 81, Issue:11
First Report of Plant-Derived β-Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model.
AID257295Inhibitory activity against human thrombin2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa.
AID1423544Anticoagulant activity in Swiss albino mouse assessed as plasma clotting time at 50 mg/kg, iv measured after 5 hrs (Rvb = 175.5 +/- 9.1 sec)2018Journal of natural products, 11-26, Volume: 81, Issue:11
First Report of Plant-Derived β-Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID766517Inhibition of thrombin (unknown origin) assessed as fibrin clot formation2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID1454783Inhibition of bovine plasma thrombin using chromogenix AB as substrate after 30 secs by UV-spectrophotometry2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243046Ki ratio of human alpha thrombin to two chain urokinase type plasminogen activator2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID215898Ratio between enzyme selectivity of trypsin /thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
AID242952Ki ratio of human alpha thrombin to trypsin2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID25171Half life in humans.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID89199In vitro concentration of inhibitor to double activated partial thromboplastin time was evaluated in human2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID112432In vivo potency for thrombin induced lethality model in anesthetized mice through intraperitoneal administration2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
AID766527Inhibition of human trypsin2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID226680Concentration required for 50% inhibition of thrombin induced platelet aggregation2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
A short synthesis of argatroban. a potent selective thrombin inhibitor.
AID182739In vivo inhibition of thrombus formation in thromboplastin-induced deep vein thrombosis (DVT) rat model after iv bolus dosing at 1 mg/kg2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
AID196086Ex vivo activated clotting time was measured in rat plasma at 1 mg/kg2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
AID766523Selectivity ratio of Ki for human plasmin to Ki for human thrombin2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID242961Ki ratio of human alpha thrombin to streptokinase2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID89373Concentration for doubling of partial thromboplastin time1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID242950Ki ratio of human alpha thrombin to plasmin2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID89374Concentration for doubling of prothrombin time1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
AID215571Selectivity ratio of IC50 of human trypsin relative to IC50 of human alpha thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID213279Inhibitory activity against bovine thrombin1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency.
AID18853% Free drug present in human plasma; Not Determined1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
AID466947Anticoagulant activity in Sprague-Dawley rat deep vein thrombosis model assessed as activated partial thromboplastin time at 1 mg/kg, iv administered for 45 mins2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
AID210661In vitro inhibition of thrombin catalytic activity using s-2238 substrate at 10 uM was measured at rat after 3 min incubation with compound2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
AID211230Inhibition of human alpha-thrombin.1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID1254403Inhibition of human thrombin using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins by spectrophotometer analysis2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.
AID243035Ki ratio of human alpha thrombin to two chain tissue type plasminogen activator2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID112433In vivo potency for thrombin induced lethality model in anesthetized mice through peroral administration2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID766525Inhibition of human plasmin2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID238527Binding affinity determined against human alpha thrombin2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
AID52187Ratio between enzyme selectivity of Coagulation factor Xa /thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID15770The concentration in plasmat; Not determined1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
AID211597Inhibition against clot-associated thrombin.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID18856% Free drug present in human plasma; Not Determined1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
AID1167011Anticoagulant activity in recombinant tissue factor and procoagulant phospholipids-stimulated human citrated plasma assessed as inhibition of thrombin peak by fluorometry based calibrated automated thrombography2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
How a β-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties.
AID89179Concentration of inhibitor in human plasma required to double the activated thromboplastin time1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.
AID766526Inhibition of human t-PA2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
AID18648The fraction of free compound available in plasma of human;not determined1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
AID362212Ratio of 2 fold prolongation of prothrombin time over 2 fold prolongation of activated partial thromboplastin time in human plasma2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.
AID211187Inhibitory activity against human thrombin (using Chromozym TH as the substrate)2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID213277Inhibitory activity against thrombin.1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
AID158186Ratio between enzyme selectivity of plasmin/thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
AID311535Inhibition of human thrombin2007Journal of natural products, Oct, Volume: 70, Issue:10
Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis.
AID211014Inhibitory activity against thrombin.2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.
AID1167012Anticoagulant activity in recombinant tissue factor and procoagulant phospholipids-stimulated human citrated plasma assessed as reduction in endogenous thrombin potential by fluorometry based calibrated automated thrombography2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
How a β-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties.
AID210730Ratio between enzyme selectivity of Tissue plasminogen activator/thrombin2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
AID233223Compound was tested for inhibition of streptokinase (SK). selectivity with respect to thrombin1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345816Human coagulation factor II, thrombin (S1: Chymotrypsin)1997Thrombosis research, Oct-15, Volume: 88, Issue:2
Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,040)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (3.56)18.7374
1990's178 (17.12)18.2507
2000's435 (41.83)29.6817
2010's303 (29.13)24.3611
2020's87 (8.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.12 (24.57)
Research Supply Index7.07 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials83 (7.64%)5.53%
Reviews194 (17.85%)6.00%
Case Studies228 (20.98%)4.05%
Observational9 (0.83%)0.25%
Other573 (52.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]